First Online: 20 January 2022
: L.E. is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative (QLHC, the study sponsor), and received grant funding from QLHC for the I-SPY TRIAL. L.E. is a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives reimbursement for time and travel. L.E. has a grant from Merck for an Investigator-initiated trial of ductal carcinoma in situ. C.C. received funding for this article from QHLC, as well as other funding from the NIH and Roche/Genentech. C.C. also provides consulting services for Quark, Vasomune and Gen1e Life Sciences. K.D.L. is a stockholder of Amgen Inc. A.D..B is a member of the Scientific Advisory Board Committee of Caris Life Sciences. All other authors report no competing interests.
Free to read: This content has been made available to all.